Objective: To evaluate CSF levels of β-amyloid (1-42) (Aβ 42 ) alone and in combination with
CSF tau for distinguishing AD from other conditions. Methods: At 10 centers in Europe and …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…

Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …

Objective To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and
β-amyloid protein ending at amino acid 42 (Aβ42) as biomarkers for Alzheimer disease (AD) …

Objectives To study the diagnostic potential of the 42 amino acid form of β-amyloid (β-amyloid
(1-42) ) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …

Alzheimer's disease is a progressive degenerative dementia characterized by the abundant
presence of neurofibrillary tangles in neurons. This study was designed to test whether the …

Background Abnormal hyperphosphorylation of the microtubule-associated protein tau and
its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of …

Background: Tau protein and the 42-amino acid form of β-amyloid (Aβ42) measured in
cerebrospinal fluid (CSF) have been proposed as potential biochemical diagnostic markers for …

An increase in cerebrospinal fluid (CSF)-total-tau, and recently also in CSF-phospho-tau, has
been found in Alzheimer's disease (AD). However, the mechanisms for these changes are …